Will the CSL share price crack the $300 barrier this week?

The CSL Limited (ASX: CSL) share price could break the $300 barrier this week – is there still time to buy the healthcare group for growth?

The CSL Limited (ASX: CSL) share price has started the new decade exactly how it finished the last – rocketing higher.

The healthcare group's shares closed at $299.30 per share last Friday and set a new all-time high in the process.

a woman

Why you should watch the CSL share price this week

There's a good chance the CSL share price could finally breach the $300 per share barrier for the first time ever.

That would be an impressive start to the new year, given the healthcare group's shares are up a whopping 38,973% since its IPO.

CSL listed on the ASX in 1994 for an adjusted 3-for-1 stock split price of just 76.6 cents per share. That means an investor who bought and held $10,000 worth of CSL shares since the IPO would be sitting on $3,897,310.70 today.

Of course, most investors would have sold their shares well short of today's all-time high. But if you were a true long-term buy-and-hold investor, that is a very tidy return from the CSL share price.

Where can I find the next CSL?

That is the multi-million-dollar question everyone would love an answer to. There have been several strong ASX growth shares emerge in recent years, all of which have potential.

The most notable ones are the "WAAAX" tech shares including Altium Limited (ASX: ALU), Appen Ltd (ASX: APX) and Xero Limited (ASX: XRO), which have seen similar growth trajectories to the CSL share price.

Outside of these, Nearmap Ltd (ASX: NEA) shares have rocketed higher in the past decade, and it has been a similar story for buy-now, pay-later companies like Zip Co Ltd (ASX: Z1P) and Afterpay Ltd (ASX: APT).

How can I make huge returns on the ASX?

To make the really big money and cash in on share price rises like CSL, you really have to be an IPO investor.

That is more difficult than you think, with evidence showing that you're likely to lose money by investing in IPOs in the long-term.

Of course, if you can ride a winner like CSL all the way to the top, you may only need one ASX growth stock to make your retirement plans a reality.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO, CSL Ltd., and ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. The Motley Fool Australia owns shares of Altium and Xero. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »